Switch theme
Sign up to access all valuation multiples
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.
2002
13
LTM Revenue n/a
LTM EBITDA n/a
-$48.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Oramed Pharmaceuticals has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Oramed Pharmaceuticals achieved revenue of n/a and an EBITDA of -$14.9M.
Oramed Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Oramed Pharmaceuticals valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.3M | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | $7.3M | -$14.9M | XXX | XXX | XXX |
| EBITDA Margin | 546% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$36.6M | $5.5M | XXX | XXX | XXX |
| Net Margin | -2728% | Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | $42.0M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Oramed Pharmaceuticals's stock price is $2.
Oramed Pharmaceuticals has current market cap of $92.7M, and EV of -$48.8M.
See Oramed Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$48.8M | $92.7M | XXX | XXX | XXX | XXX | $-0.36 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Oramed Pharmaceuticals has market cap of $92.7M and EV of -$48.8M.
Oramed Pharmaceuticals's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Oramed Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Oramed Pharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$48.8M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | 3.3x | XXX | XXX | XXX |
| P/E | -4.9x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 5.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpOramed Pharmaceuticals's NTM/LTM revenue growth is n/a
Oramed Pharmaceuticals's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.0M for the same period.
Over next 12 months, Oramed Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Oramed Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Oramed Pharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -100% | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | -303% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.0M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Oramed Pharmaceuticals acquired XXX companies to date.
Last acquisition by Oramed Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Oramed Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Oramed Pharmaceuticals founded? | Oramed Pharmaceuticals was founded in 2002. |
| Where is Oramed Pharmaceuticals headquartered? | Oramed Pharmaceuticals is headquartered in United States of America. |
| How many employees does Oramed Pharmaceuticals have? | As of today, Oramed Pharmaceuticals has 13 employees. |
| Who is the CEO of Oramed Pharmaceuticals? | Oramed Pharmaceuticals's CEO is Mr. Nadav Kidron. |
| Is Oramed Pharmaceuticals publicy listed? | Yes, Oramed Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Oramed Pharmaceuticals? | Oramed Pharmaceuticals trades under ORMP ticker. |
| When did Oramed Pharmaceuticals go public? | Oramed Pharmaceuticals went public in 2007. |
| Who are competitors of Oramed Pharmaceuticals? | Similar companies to Oramed Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Oramed Pharmaceuticals? | Oramed Pharmaceuticals's current market cap is $92.7M |
| Is Oramed Pharmaceuticals profitable? | Yes, Oramed Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
